HRP20090434T1 - Sastavi kontroliranog otpuštanja za interferon koji se temelji na pegt/pbt blok kopolimerima - Google Patents
Sastavi kontroliranog otpuštanja za interferon koji se temelji na pegt/pbt blok kopolimerima Download PDFInfo
- Publication number
- HRP20090434T1 HRP20090434T1 HR20090434T HRP20090434T HRP20090434T1 HR P20090434 T1 HRP20090434 T1 HR P20090434T1 HR 20090434 T HR20090434 T HR 20090434T HR P20090434 T HRP20090434 T HR P20090434T HR P20090434 T1 HRP20090434 T1 HR P20090434T1
- Authority
- HR
- Croatia
- Prior art keywords
- block copolymers
- composition
- pegt
- poly
- controlled release
- Prior art date
Links
- 229920001400 block copolymer Polymers 0.000 title claims abstract 5
- 102000014150 Interferons Human genes 0.000 title claims abstract 4
- 108010050904 Interferons Proteins 0.000 title claims abstract 4
- 229940079322 interferon Drugs 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000013270 controlled release Methods 0.000 title abstract 2
- -1 poly(ethylene glycol) Polymers 0.000 claims abstract 8
- 238000000034 method Methods 0.000 claims abstract 6
- 229920001707 polybutylene terephthalate Polymers 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 3
- 229940047124 interferons Drugs 0.000 claims abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 4
- 239000008346 aqueous phase Substances 0.000 claims 3
- 239000012071 phase Substances 0.000 claims 3
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000002357 osmotic agent Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 150000003839 salts Chemical group 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 230000001804 emulsifying effect Effects 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Postupak pripreme mikrodijelova, naznačen time, da isti sadrže jedan ili više aktivnih spojeva odabranih iz grupe interferona i jednog ili više biorazgradivih blok kopolimera stvorenih od poli(etilenglikol) tereftalata (PEGT) i poli(butilen tereftalata) (PBT), koji se sastoje od sljedećih koraka: (a) priprema emulzije koja se sastoji od (aa) vodene unutarnje faze koja sadrži jedan ili više aktivnih spojeva, i (ab) organske vanjske faze koja sadrži jedan ili više biorazgradivih blok kopolimera i bar jedno organsko otapalo; (b) ukrućivanje jednog ili više biorazgradivih blok kopolimera u mikrodijelove otklanjanjem barem dijela organskog otapala iz emulzije pripremljene u koraku (a); (c) prikupljanje i sušenje mikrodijelova oblikovanih u koraku (b) pri čemu korak (b) se provodi emulzifikacijom emulzije pripremljene u koraku (a) i povezane vodene faze da bi se dobila w/o/w-dvostruka emulzija, pri čemu povezana vodena faza sadrži osmotski agens, pri čemu je osmolalnost povezane vodene faze viša od one vodene unutarnje faze. Patent sadrži još 4 patentna zahtjeva.
Claims (5)
1. Postupak pripreme mikrodijelova, naznačen time, da isti sadrže jedan ili više aktivnih spojeva odabranih iz grupe interferona i jednog ili više biorazgradivih blok kopolimera stvorenih od poli(etilenglikol) tereftalata (PEGT) i poli(butilen tereftalata) (PBT), koji se sastoje od sljedećih koraka:
(a) priprema emulzije koja se sastoji od
(aa) vodene unutarnje faze koja sadrži jedan ili više aktivnih spojeva, i
(ab) organske vanjske faze koja sadrži jedan ili više biorazgradivih blok kopolimera i bar jedno organsko otapalo;
(b) ukrućivanje jednog ili više biorazgradivih blok kopolimera u mikrodijelove otklanjanjem barem dijela organskog otapala iz emulzije pripremljene u koraku (a);
(c) prikupljanje i sušenje mikrodijelova oblikovanih u koraku (b) pri čemu korak (b) se provodi emulzifikacijom emulzije pripremljene u koraku (a) i povezane vodene faze da bi se dobila w/o/w-dvostruka emulzija, pri čemu povezana vodena faza sadrži osmotski agens, pri čemu je osmolalnost povezane vodene faze viša od one vodene unutarnje faze.
2. Postupak prema zahtjevu 1, naznačen time, da je osmotski agens sol.
3. Postupak prema zahtjevu 2, naznačen time, da je sol natrij klorid.
4. Postupak prema zahtjevu 3, naznačen time, da je natrij klorid prisutan u razini od oko 3 do oko 6 wt.%.
5. Postupak prema bilo kojem od ranijih zahtjeva, naznačen time, da je interferon izabran iz grupe alfa-interferona.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05075043A EP1679065A1 (en) | 2005-01-07 | 2005-01-07 | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
| PCT/NL2006/000006 WO2006085747A1 (en) | 2005-01-07 | 2006-01-06 | Controlled release compositions for interferon based on pegt/pbt block copolymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090434T1 true HRP20090434T1 (hr) | 2009-09-30 |
Family
ID=34937981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090434T HRP20090434T1 (hr) | 2005-01-07 | 2009-08-11 | Sastavi kontroliranog otpuštanja za interferon koji se temelji na pegt/pbt blok kopolimerima |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7736674B2 (hr) |
| EP (4) | EP1679065A1 (hr) |
| JP (2) | JP2008526837A (hr) |
| KR (2) | KR101354521B1 (hr) |
| CN (2) | CN101137349B (hr) |
| AT (1) | ATE431134T1 (hr) |
| AU (2) | AU2006213168B2 (hr) |
| BR (1) | BRPI0606514A2 (hr) |
| CA (1) | CA2594434A1 (hr) |
| CY (1) | CY1109297T1 (hr) |
| DE (1) | DE602006006797D1 (hr) |
| DK (1) | DK1843749T3 (hr) |
| ES (1) | ES2327267T3 (hr) |
| HK (1) | HK1152644A1 (hr) |
| HR (1) | HRP20090434T1 (hr) |
| IL (2) | IL184431A (hr) |
| MX (1) | MX2007008293A (hr) |
| PL (1) | PL1843749T3 (hr) |
| PT (1) | PT1843749E (hr) |
| RS (1) | RS51129B (hr) |
| RU (2) | RU2409348C2 (hr) |
| SG (1) | SG158856A1 (hr) |
| SI (1) | SI1843749T1 (hr) |
| WO (1) | WO2006085747A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1679065A1 (en) | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
| US8137661B2 (en) | 2007-07-25 | 2012-03-20 | Biolex Therapeutics, Inc. | Controlled release interferon drug products and treatment of HCV infections using same |
| EP2055299A1 (en) * | 2007-10-23 | 2009-05-06 | Koninklijke Philips Electronics N.V. | Methods for preparing polymer microparticles |
| WO2009053885A2 (en) | 2007-10-23 | 2009-04-30 | Koninklijke Philips Electronics N.V. | Methods for preparing polymer microparticles |
| EP2323630B1 (en) * | 2008-06-30 | 2014-11-19 | Silenseed Ltd | Methods, compositions and systems for local delivery of drugs |
| AU2010220324A1 (en) | 2009-03-05 | 2011-09-01 | Ascendis Pharma As | Interferon alpha carrier prodrugs |
| WO2012135010A2 (en) * | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
| UY34402A (es) | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CH707030B1 (de) | 2011-10-21 | 2015-03-13 | Abbvie Inc | Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| WO2016046817A1 (en) | 2014-09-24 | 2016-03-31 | Vital Beverages Global Inc. | Compositions and methods for selective gi tract delivery |
| EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF |
| JP2022539602A (ja) | 2019-07-12 | 2022-09-12 | ビーエーエスエフ ソシエタス・ヨーロピア | 揮発性有機活性剤が充填された微粒子を製造する方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL137652C (hr) * | 1962-07-11 | |||
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5192743A (en) * | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
| DE69332500T2 (de) | 1992-04-24 | 2004-01-29 | Chienna Bv | Vorrichtung zum vermeiden von gewebeadhäsionen |
| US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
| EP0582459B1 (en) * | 1992-08-07 | 1998-01-07 | Takeda Chemical Industries, Ltd. | Production of microcapsules of water-soluble drugs |
| US5643605A (en) * | 1993-10-25 | 1997-07-01 | Genentech, Inc. | Methods and compositions for microencapsulation of adjuvants |
| US6117455A (en) | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
| US5612052A (en) * | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| DE19545257A1 (de) * | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| JP2000501394A (ja) | 1995-11-30 | 2000-02-08 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ガンの診断および処置のための方法および組成物 |
| US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
| US5980948A (en) * | 1996-08-16 | 1999-11-09 | Osteotech, Inc. | Polyetherester copolymers as drug delivery matrices |
| EP2030614A1 (en) | 1997-02-27 | 2009-03-04 | Novartis AG | Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin |
| CA2287534C (en) * | 1997-04-17 | 2004-12-28 | Amgen Inc. | Biodegradable microparticles for the sustained delivery of therapeutic drugs |
| AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| US6531154B1 (en) * | 1997-06-10 | 2003-03-11 | Brown University Research Foundation | Modulated release from biocompatible polymers |
| JP2001521004A (ja) * | 1997-10-24 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | 脂肪酸−アシル化インスリン類似体 |
| US6270802B1 (en) * | 1998-10-28 | 2001-08-07 | Oakwood Laboratories L.L.C. | Method and apparatus for formulating microspheres and microcapsules |
| US6194006B1 (en) * | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| CA2360232A1 (en) * | 1999-01-12 | 2000-07-20 | Tamio Mizukami | Telomerase inhibitors |
| US6204308B1 (en) * | 1999-03-01 | 2001-03-20 | Novartis Ag | Organic compounds |
| US20030206928A1 (en) * | 1999-04-07 | 2003-11-06 | Pertti Tormala | Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices |
| US6291013B1 (en) * | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
| CN1361685A (zh) | 1999-07-15 | 2002-07-31 | 武田药品工业株式会社 | 缓释组合物、其制备方法和用途 |
| EP1090928B1 (en) | 1999-09-30 | 2004-05-26 | Chienna B.V. | Polymers loaded with bioactive agents |
| US6465425B1 (en) * | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| US6479065B2 (en) * | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| US6471995B1 (en) * | 2000-09-27 | 2002-10-29 | Alkermes Controlled Therapeutics, Inc. Ii | Apparatus and method for preparing microparticles using liquid-liquid extraction |
| JP4557409B2 (ja) * | 2000-11-13 | 2010-10-06 | 日東電工株式会社 | 多孔質ポリイミドの製造方法及び多孔質ポリイミド |
| ATE309788T1 (de) | 2000-12-13 | 2005-12-15 | Merckle Gmbh | Mikropartikel mit verbessertem freisetzungsprofil und verfahren zu deren herstellung |
| US8637077B2 (en) * | 2000-12-28 | 2014-01-28 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
| RU2191012C1 (ru) | 2001-06-20 | 2002-10-20 | Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ | Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы |
| EP1438019A1 (en) | 2001-10-24 | 2004-07-21 | PARI GmbH Spezialisten für effektive Inhalation | Kit for the preparation of a pharmaceutical composition |
| EP1443907A1 (en) * | 2001-11-12 | 2004-08-11 | Alkermes Controlled Therapeutics, Inc. | Biocompatible polymer blends and uses thereof |
| TWI252111B (en) * | 2001-12-14 | 2006-04-01 | Solvay Pharm Gmbh | Matrix film tablet with controlled release of a natural mixture of conjugated estrogens |
| KR100994658B1 (ko) * | 2001-12-26 | 2010-11-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 신규 마이크로스피어 및 이들의 제조 방법 |
| DK1532985T3 (en) * | 2002-06-25 | 2016-12-05 | Takeda Pharmaceuticals Co | PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE |
| CA2532302C (en) * | 2003-07-15 | 2016-12-20 | Pr Pharmaceuticals, Inc. | Method for the preparation of controlled release formulations |
| JP5030292B2 (ja) * | 2004-04-15 | 2012-09-19 | アミリン・ファーマシューティカルズ，インコーポレイテッド | ポリマーを基にした持続放出性装置 |
| EP1679065A1 (en) | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
-
2005
- 2005-01-07 EP EP05075043A patent/EP1679065A1/en not_active Withdrawn
-
2006
- 2006-01-06 WO PCT/NL2006/000006 patent/WO2006085747A1/en active Application Filing
- 2006-01-06 BR BRPI0606514-7A patent/BRPI0606514A2/pt not_active IP Right Cessation
- 2006-01-06 EP EP10182460A patent/EP2266535B1/en active Active
- 2006-01-06 KR KR1020107020687A patent/KR101354521B1/ko not_active IP Right Cessation
- 2006-01-06 KR KR1020077018068A patent/KR20070118225A/ko not_active Application Discontinuation
- 2006-01-06 PL PL06700417T patent/PL1843749T3/pl unknown
- 2006-01-06 MX MX2007008293A patent/MX2007008293A/es active IP Right Grant
- 2006-01-06 DE DE602006006797T patent/DE602006006797D1/de active Active
- 2006-01-06 RS RSP-2009/0358A patent/RS51129B/sr unknown
- 2006-01-06 JP JP2007550316A patent/JP2008526837A/ja active Pending
- 2006-01-06 ES ES06700417T patent/ES2327267T3/es active Active
- 2006-01-06 CN CN200680007430XA patent/CN101137349B/zh not_active Expired - Fee Related
- 2006-01-06 RU RU2007130090/15A patent/RU2409348C2/ru not_active IP Right Cessation
- 2006-01-06 EP EP06700417A patent/EP1843749B1/en active Active
- 2006-01-06 PT PT06700417T patent/PT1843749E/pt unknown
- 2006-01-06 SI SI200630366T patent/SI1843749T1/sl unknown
- 2006-01-06 AU AU2006213168A patent/AU2006213168B2/en not_active Ceased
- 2006-01-06 CA CA002594434A patent/CA2594434A1/en not_active Abandoned
- 2006-01-06 EP EP07120539A patent/EP1886668B1/en active Active
- 2006-01-06 DK DK06700417T patent/DK1843749T3/da active
- 2006-01-06 AT AT06700417T patent/ATE431134T1/de active
- 2006-01-06 SG SG201000063-6A patent/SG158856A1/en unknown
- 2006-01-06 CN CN200910207704A patent/CN101791396A/zh active Pending
-
2007
- 2007-07-05 IL IL184431A patent/IL184431A/en not_active IP Right Cessation
- 2007-07-06 US US11/774,107 patent/US7736674B2/en not_active Expired - Fee Related
-
2009
- 2009-05-15 US US12/466,430 patent/US7867518B2/en not_active Expired - Fee Related
- 2009-08-10 CY CY20091100844T patent/CY1109297T1/el unknown
- 2009-08-11 HR HR20090434T patent/HRP20090434T1/hr unknown
- 2009-11-25 US US12/625,929 patent/US8163307B2/en not_active Expired - Fee Related
-
2010
- 2010-09-14 JP JP2010205413A patent/JP4887542B2/ja not_active Expired - Fee Related
- 2010-09-15 IL IL208175A patent/IL208175A0/en unknown
- 2010-09-20 RU RU2010138739/15A patent/RU2010138739A/ru unknown
- 2010-09-24 AU AU2010224413A patent/AU2010224413B2/en not_active Ceased
-
2011
- 2011-06-28 HK HK11106616.8A patent/HK1152644A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090434T1 (hr) | Sastavi kontroliranog otpuštanja za interferon koji se temelji na pegt/pbt blok kopolimerima | |
| CY1113969T1 (el) | Ανευ-αλβουμινης συνταγοποιησεις παραγοντα viii | |
| HRP20150272T1 (hr) | Oblik s produljenim oslobađanjem na bazi polimera | |
| AR011002A1 (es) | Composicion de champu para estilizar el cabello | |
| HRP20131173T4 (hr) | Vodeni farmaceutski pripravci koji sadrže boratno-poliolne komplekse | |
| DE60319727D1 (de) | Verfahren zum auflösen lipophiler verbindungen, und kosmetische zusammensetzung. | |
| CO4940389A1 (es) | Composiciones de perfume de una y dos fases para reducir el olor corporal y metodo para su uso | |
| NO20034492D0 (no) | HSA-frie formuleringer av Interferon-<beta> | |
| RU2003108822A (ru) | Улучшенная противоопухолевая композиция на основе паклитаксела | |
| ME00408B (me) | Preparati insulina koji ne sadrže cink ili sadrže male količine cinka koji imaju poboljšanu stabilnost | |
| AR041913A1 (es) | Formulaciones de deposito de liberacion controlada | |
| NO20073334L (no) | Nanopartikulaert benzotiofenformuleringer | |
| DE60335101D1 (de) | Antimikrobielles polypeptid und nutzung davon | |
| AR033243A1 (es) | Un antitranspirante y/o desodorante de fases, aplicable a bolilla | |
| ATE348602T1 (de) | Nanoteilchen zur verabreichung von wirkstoffen, verfahren zur herstellung dieser teilchen und diese enthaltende zusammensetzung | |
| JP2009215298A5 (hr) | ||
| JP2005533081A5 (hr) | ||
| DK1656418T3 (da) | Stabiliseringssystem for halogenholdige polymerer | |
| DE50300410D1 (de) | In Wasser redispergierbare Polymerpulver-Zusammensetzungen mit abbindebeschleunigender Wirkung | |
| ATE526941T1 (de) | Kosmetische zusammensetzung vom wasser/wasser- emulsionstyp auf basis von tensiden und kationischen polymeren | |
| JP2014089482A (ja) | コンタクトレンズ装着液 | |
| RU2021109916A (ru) | Композиции клостридиального токсина и гиалуроновой кислоты | |
| BRPI0409877A (pt) | agentes preventivos ou remédios para doenças hepáticas | |
| RU2004134413A (ru) | Геминпептид, его фармацевтически приемлемые соли и применение в качестве противовирусного и вирулецидного агента | |
| BRPI0509533A (pt) | compostos de agentes antivirais, composição farmacêutica e seus usos |